Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

People who live with narcolepsy — about ... GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. In order to bring it ...

AXSM announced that the FDA has approved Symbravo (meloxicam ... Axsome’s second marketed drug, Sunosi, is approved for treating narcolepsy. The company acquired U.S. rights to Sunosi from ...

Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

The FDA expanded the approval of Lumryz extended-release oral suspension for treatment of pediatric narcolepsy. The Food and Drug Administration (FDA) has expanded the approval of Lumryz ...

For more comprehensive information about these two drugs, you can refer to our Provigil and Adderall articles. Adderall is FDA approved to treat narcolepsy in children ages 6 years and older.

Shares in Axsome Therapeutics have rocketed on FDA ... approved in March 2019 and is administered as a nasal spray twice a week for four weeks. However, it has a broader label as unlike J&J's drug ...

This medication is Food and Drug Administration (FDA)–approved to treat ADHD and narcolepsy (a medical condition characterized by overwhelming daytime drowsiness). Adderall IR is available as a tablet ...

In addition, Medicaid plans offered by Independence Blue Cross must comply with the law governing the Medicaid Drug Rebate Program and cover all FDA-approved drugs, including those granted ...